Cargando…

Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies

To investigate the effects of gabapentin, a structural analog of γ-amino butyric acid (GABA), on the inflammatory response of lipopolysaccharide (LPS)-stimulated rabbit corneal cells (SIRC) and on endotoxin-induced uveitis (EIU) in rabbits. We investigated the LPS-induced expression of several infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Anfuso, Carmelina D., Olivieri, Melania, Fidilio, Annamaria, Lupo, Gabriella, Rusciano, Dario, Pezzino, Salvatore, Gagliano, Caterina, Drago, Filippo, Bucolo, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378778/
https://www.ncbi.nlm.nih.gov/pubmed/28420991
http://dx.doi.org/10.3389/fphar.2017.00173
_version_ 1782519477507719168
author Anfuso, Carmelina D.
Olivieri, Melania
Fidilio, Annamaria
Lupo, Gabriella
Rusciano, Dario
Pezzino, Salvatore
Gagliano, Caterina
Drago, Filippo
Bucolo, Claudio
author_facet Anfuso, Carmelina D.
Olivieri, Melania
Fidilio, Annamaria
Lupo, Gabriella
Rusciano, Dario
Pezzino, Salvatore
Gagliano, Caterina
Drago, Filippo
Bucolo, Claudio
author_sort Anfuso, Carmelina D.
collection PubMed
description To investigate the effects of gabapentin, a structural analog of γ-amino butyric acid (GABA), on the inflammatory response of lipopolysaccharide (LPS)-stimulated rabbit corneal cells (SIRC) and on endotoxin-induced uveitis (EIU) in rabbits. We investigated the LPS-induced expression of several inflammatory mediators, such as TNF-α, IL-1β, cPLA(2), COX-2, and PGE(2) in the SIRC cells with or without gabapentin treatment. Gabapentin treatment significantly (p < 0.05) attenuated cytokines production, cPLA(2) activation, COX-2 expression, and PGE(2) levels in SIRC. EIU was induced by an intraocular injection of 0.1 μg of LPS in albino rabbit eye. After 7 and 24 h from LPS injection clinical signs of ocular inflammation were examined by slit lamp with or without topical treatment of 0.5% gabapentin. Tears, aqueous, cornea, conjunctiva, and iris-ciliary body were collected and inflammatory biomarkers assessed. Topical treatment with gabapentin significantly (p < 0.05) reduced clinical signs and biomarkers of inflammation compared with the LPS group both at 7 and 24 h. In conclusion, the results generated in the present study suggest that ophthalmic formulation based on gabapentin may be useful in the treatment of inflammatory conditions associated to ocular pain such as uveitis, and that clinical studies to evaluate this possibility may be warranted.
format Online
Article
Text
id pubmed-5378778
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-53787782017-04-18 Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies Anfuso, Carmelina D. Olivieri, Melania Fidilio, Annamaria Lupo, Gabriella Rusciano, Dario Pezzino, Salvatore Gagliano, Caterina Drago, Filippo Bucolo, Claudio Front Pharmacol Pharmacology To investigate the effects of gabapentin, a structural analog of γ-amino butyric acid (GABA), on the inflammatory response of lipopolysaccharide (LPS)-stimulated rabbit corneal cells (SIRC) and on endotoxin-induced uveitis (EIU) in rabbits. We investigated the LPS-induced expression of several inflammatory mediators, such as TNF-α, IL-1β, cPLA(2), COX-2, and PGE(2) in the SIRC cells with or without gabapentin treatment. Gabapentin treatment significantly (p < 0.05) attenuated cytokines production, cPLA(2) activation, COX-2 expression, and PGE(2) levels in SIRC. EIU was induced by an intraocular injection of 0.1 μg of LPS in albino rabbit eye. After 7 and 24 h from LPS injection clinical signs of ocular inflammation were examined by slit lamp with or without topical treatment of 0.5% gabapentin. Tears, aqueous, cornea, conjunctiva, and iris-ciliary body were collected and inflammatory biomarkers assessed. Topical treatment with gabapentin significantly (p < 0.05) reduced clinical signs and biomarkers of inflammation compared with the LPS group both at 7 and 24 h. In conclusion, the results generated in the present study suggest that ophthalmic formulation based on gabapentin may be useful in the treatment of inflammatory conditions associated to ocular pain such as uveitis, and that clinical studies to evaluate this possibility may be warranted. Frontiers Media S.A. 2017-04-04 /pmc/articles/PMC5378778/ /pubmed/28420991 http://dx.doi.org/10.3389/fphar.2017.00173 Text en Copyright © 2017 Anfuso, Olivieri, Fidilio, Lupo, Rusciano, Pezzino, Gagliano, Drago and Bucolo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Anfuso, Carmelina D.
Olivieri, Melania
Fidilio, Annamaria
Lupo, Gabriella
Rusciano, Dario
Pezzino, Salvatore
Gagliano, Caterina
Drago, Filippo
Bucolo, Claudio
Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies
title Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies
title_full Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies
title_fullStr Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies
title_full_unstemmed Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies
title_short Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies
title_sort gabapentin attenuates ocular inflammation: in vitro and in vivo studies
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378778/
https://www.ncbi.nlm.nih.gov/pubmed/28420991
http://dx.doi.org/10.3389/fphar.2017.00173
work_keys_str_mv AT anfusocarmelinad gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT olivierimelania gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT fidilioannamaria gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT lupogabriella gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT ruscianodario gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT pezzinosalvatore gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT gaglianocaterina gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT dragofilippo gabapentinattenuatesocularinflammationinvitroandinvivostudies
AT bucoloclaudio gabapentinattenuatesocularinflammationinvitroandinvivostudies